Cannim Group Back Medicinal Cannabis Research to Address Crisis Point in Australian Women’s Health.

SYDNEY, AUSTRALIA – Australian Medicinal Cannabis company Cannim have partnered with the National Institute of Complementary Medicine (Western Sydney University) on groundbreaking studies examining the effectiveness of medicinal cannabis in treating women’s health; initially focusing on Primary Dysmenorrhea (Period Pain) for women aged 20+, and Sleep Disturbance during Menopause for women aged 45-65.

Cannim have assembled a team of Australia’s foremost women’s health researchers to spearhead investigation into medicinal cannabis as a treatment option for health conditions affecting women, which cause significant absenteeism and reduced productivity at school, university, and workplaces, with an estimated annual cost to Australians of $14 billion.

Full press release